Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial

Stephen N Davis, William Duckworth, Nicholas Emanuele, Rodney A Hayward, Wyndy L Wiitala, Lizy Thottapurathu, Domenic J Reda, Peter D Reaven, Investigators of the Veterans Affairs Diabetes Trial, Stephen N Davis, William Duckworth, Nicholas Emanuele, Rodney A Hayward, Wyndy L Wiitala, Lizy Thottapurathu, Domenic J Reda, Peter D Reaven, Investigators of the Veterans Affairs Diabetes Trial

Abstract

Objective: To determine the risk factors for severe hypoglycemia and the association between severe hypoglycemia and serious cardiovascular adverse events and cardiovascular and all-cause mortality in the Veterans Affairs Diabetes Trial (VADT).

Research design and methods: This post hoc analysis of data from the VADT included 1,791 military veterans (age 60.5 ± 9.0 years) with suboptimally controlled type 2 diabetes (HbA1c 9.4 ± 2.0%) of 11.5 ± 7.5 years disease duration with or without known cardiovascular disease and additional cardiovascular risk factors. Participants were randomized to intensive (HbA1c <7.0%) versus standard (HbA1c <8.5%) glucose control.

Results: The rate of severe hypoglycemia in the intensive treatment group was 10.3 per 100 patient-years compared with 3.7 per 100 patient-years in the standard treatment group (P < 0.001). In multivariable analysis, insulin use at baseline (P = 0.02), proteinuria (P = 0.009), and autonomic neuropathy (P = 0.01) were independent risk factors for severe hypoglycemia, and higher BMI was protective (P = 0.017). Severe hypoglycemia within the past 3 months was associated with an increased risk of serious cardiovascular events (P = 0.032), cardiovascular mortality (P = 0.012), and total mortality (P = 0.024). However, there was a relatively greater increased risk for total mortality in the standard group compared with the intensive group (P = 0.019). The association between severe hypoglycemia and cardiovascular events increased significantly as overall cardiovascular risk increased (P = 0.012).

Conclusions: Severe hypoglycemic episodes within the previous 3 months were associated with increased risk for major cardiovascular events and cardiovascular and all-cause mortality regardless of glycemic treatment group assignment. Standard therapy further increased the risk for all-cause mortality after severe hypoglycemia.

Trial registration: ClinicalTrials.gov NCT00032487.

© 2018 by the American Diabetes Association.

References

    1. Gerstein HC, Miller ME, Byington RP, et al. .; Action to Control Cardiovascular Risk in Diabetes Study Group . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
    1. Patel A, MacMahon S, Chalmers J, et al. .; ADVANCE Collaborative Group . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572
    1. Miller ME, Bonds DE, Gerstein HC, et al. .; ACCORD Investigators . The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444.
    1. Bonds DE, Miller ME, Bergenstal RM, et al. . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909.
    1. Mellbin LG, Rydén L, Riddle MC, et al. .; ORIGIN Trial Investigators . Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J 2013;34:3137–3144
    1. Finfer S, Chittock DR, Su SY, et al. .; NICE-SUGAR Study Investigators . Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297
    1. Bedenis R, Price AH, Robertson CM, et al. . Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care 2014;37:3301–3308
    1. Frye RL, August P, Brooks MM, et al. .; BARI 2D Study Group . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515
    1. Duckworth W, Abraira C, Moritz T, et al. .; VADT Investigators . Glucose control and vascular complications in veterans with type 2 Diabetes [published correction appears in N Engl J Med 2009;361:1028]. N Engl J Med 2009;360:129–139
    1. Abraira C, Duckworth W, McCarren M, et al. .; VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2 . Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314–322
    1. American Diabetes Association Position statement: standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25:S33–S49
    1. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004;27:201–207
    1. Pieber TR, Marso SP, McGuire DK, et al. .; DEVOTE Study Group . DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 2018;61:58–65
    1. Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB; LEADER Publication Committee on behalf of the LEADER Trial Investigators . Hypoglycemia, cardiovascular outcomes, and death: the LEADER experience. Diabetes Care 2018;41:1783–1791
    1. Christensen TF, Tarnow L, Randløv J, et al. . QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia 2010;53:2036–2041
    1. Joy NG, Tate DB, Younk LM, Davis SN. Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy humans. Diabetes 2015;64:2571–2580
    1. Zoungas S, Patel A, Chalmers J, et al. .; ADVANCE Collaborative Group . Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410–1418
    1. Riddle MC. Counterpoint: intensive glucose control and mortality in ACCORD--still looking for clues. Diabetes Care 2010;33:2722–2724
    1. Seaquist ER, Miller ME, Bonds DE, et al. .; ACCORD Investigators . The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012;35:409–414
    1. Davis SN, Shavers C, Mosqueda-Garcia R, Costa F. Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans. Diabetes 1997;46:1328–1335
    1. Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes 2009;58:701–709
    1. Joy NG, Mikeladze M, Younk LM, Tate DB, Davis SN. Effects of equivalent sympathetic activation during hypoglycemia on endothelial function and pro-atherothrombotic balance in healthy individuals and obese standard treated type 2 diabetes. Metabolism 2016;65:1695–1705
    1. Saremi A, Bahn GD, Reaven PD; Veterans Affairs Diabetes Trial (VADT) . A link between hypoglycemia and progression of atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care 2016;39:448–454
    1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. .. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅